Heron TherapeuticsFRA:AXD2 -6.21%49 Days Payable is 76.55 as of Mar. 2026, which is 15% above its 10-year median of 66.46. GuruFocus rates FRA:AXD2 with a GF Score™ of 49/100 and a GF Value™ of €1.28 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 707 Biotechnology companies, Heron Therapeutics ranks worse than 55.16% on this metric.
The historical rank and industry rank for Heron Therapeutics's Days Payable or its related term are showing as below:
FRA:AXD2'
s Days Payable Range Over the Past 10 Years
Min: 17.85 Med: 66.46 Max: 58342.64
Current: 91.15
During the past 13 years, Heron Therapeutics's highest Days Payable was 58342.64. The lowest was 17.85. And the median was 66.46.
FRA:AXD2's Days Payable is ranked worse than 55.16% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs FRA:AXD2: 91.15
Heron Therapeutics's Days Payable
declined
from Mar. 2025 (131.77) to Mar. 2026 (76.55).
It may suggest that Heron Therapeuticsaccelerated paying its suppliers.
Heron Therapeutics Days Payable Related Terms
Heron Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Heron Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AXD2 vs PLYX, ORMP, SPRO: Days Payable Comparison
For the Biotechnology subindustry, Heron Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heron Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Heron Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Heron Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heron Therapeutics (FRA:AXD2) has a Days Payable of 76.55 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Heron Therapeutics and its competitors. This is 15% above median its historical median of 66.46. Over the past decade, Heron Therapeutics' Days Payable has ranged from 17.85 to 58,342.64. According to the industry distribution chart, Heron Therapeutics ranks #390 out of 707 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Heron Therapeutics' Days Payable too high?
Heron Therapeutics' current Days Payable of 76.55 is 15% above median its 10-year median of 66.46. Over the past 10 years, this metric has ranged from a low of 17.85 to a high of 58,342.64. The Biotechnology industry median Days Payable is 113.76. Heron Therapeutics' value of 76.55 is 32.7% below this industry median. Based on the distribution chart, Heron Therapeutics ranks #390 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Heron Therapeutics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Heron Therapeutics' Days Payable compare to PLYX and ORMP?
According to the Biotechnology industry distribution chart, Heron Therapeutics ranks #390 out of 707 companies for Days Payable. This places Heron Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. Heron Therapeutics' value of 76.55 is 32.7% below this benchmark. Historically, Heron Therapeutics' own Days Payable has ranged from 17.85 to 58,342.64 over the past decade. While the company's 10-year median is 66.46 vs. the industry median of 113.76, Heron Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heron Therapeutics's current Days Payable of 76.55 is 32.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Heron Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heron Therapeutics's current Days Payable is 76.55, which is 15% above median its own 10-year median of 66.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heron Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Heron Therapeutics (FRA:AXD2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.28, compared to a current price of €0.35 — trading 72.4% below its estimated fair value. The current Days Payable is 76.55, which is 15% above median its 10-year median of 66.46 and 32.7% below the Biotechnology industry median of 113.76. Heron Therapeutics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Heron Therapeutics (FRA:AXD2), the current Days Payable is 76.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?
Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued.
The current stock price of €0.35 is trading 72.4% below its estimated GF Value™ of €1.28.
GuruFocus considers Heron Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:AXD2:
Days Payable: 76.55 (15% above median its 10-year median of 66.46)
GF Value™: €1.28 vs. price of €0.35 (72.4% below fair value)
Industry Position: 32.7% below the Biotechnology median (#390 of 707)
No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score
Get the complete analysis for FRA:AXD2
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AXD2 has been successfully added to your 
